Telavancin and hydroxy propyl-β-cyclodextrin clearance during continuous renal replacement therapy: An in vitro study

International Journal of Artificial Organs

Volumn 32, Issue 10, 2009, Pages 745-751

  Patel, Jignesh H ^a   Churchwell, Mariann D ^b   Seroogy, Julie D ^c   Barriere, Steven L ^d   Grio, Maricor ^e   Mueller, Bruce A ^f  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF TOLEDO   (United States)

^c PharmacoFore Inc ^*  (United States)

^d THERAVANCE INC   (United States)

^e ARNOLD PALMER HOSPITAL FOR CHILDREN   (United States)

^f UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Acute renal failure; Continuous hemodialysis; Continuous hemofiltration; Continuous renal replacement therapy; Pharmacokinetics; Telavancin

Indexed keywords

ANTIMICROBIAL AGENTS; CYCLODEXTRINS; FLOW RATE; HEMODIALYZERS; PHARMACOKINETICS; ULTRAFILTRATION;

ACUTE RENAL FAILURE; CONTINUOUS HEMODIALYSIS; CONTINUOUS HEMOFILTRATION; CONTINUOUS RENAL REPLACEMENT THERAPY; DIALYSATES; HAEMODIALYSIS; HEMOFILTRATION; RENAL FAILURE; RENAL REPLACEMENT THERAPIES; TELAVANCIN;

DIALYSIS;

2 HYDROXYPROPYL BETA CYCLODEXTRIN; POLYSULFONE; TELAVANCIN;

ARTICLE; CLEARANCE; CONTINUOUS HEMOFILTRATION; CONTINUOUS RENAL REPLACEMENT THERAPY; CONTROLLED STUDY; COW; DIALYSATE; DIALYSIS MEMBRANE; FLOW RATE; HEMODIALYSIS; IN VITRO STUDY; KIDNEY CLEARANCE; NONHUMAN; ULTRAFILTRATION;

EID: 71449122218     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139880903201006     Document Type: Article

References (19)

1. Leuthner KD, Cheung CM, Rybak MJ. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant staphylococcus aureus. J Antimicrob Chemother 2006; 58: 338-43.
2. Hegde SS, Reyes N, Wiens T, et al. Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria. Antimicrob Agents Chemother 2004; 48: 3043-50.
3. Monbaliu J, Van Beijstervedt L, Meuldermans W, Szathmary S, Heykants J. Disposition of HP-β-CD in experimental animals. In: Duchene D (ed). Minutes of the 5th International Symposium on Cyclodextrins. Paris: Editions de Santé; 1990. p 514-17.
4. Zhou H, Goldman M, Wu J, et al. A pharmacokinetic study of intravenous itraconazole followed by oral administration of itraconazole capsules in patients with advanced human immunodeficiency virus infection. J Clin Pharmacol 1998; 38: 593-602.
5. Charneski L, Patel PN, Sym D. Telavancin: a novel lipoglycopeptide antibiotic. Annals Pharmacother 2009: 43: 928-37.
6. Shaw JP, Seroogy J, Kaniga K, Higgins DL, Kitt M, Barriere S. Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob Agents Chemother 2005; 49: 195-201.
7. Churchwell MD, Pasko DA, Mueller BA. Daptomycin clearance during modeled continuous renal replacement therapy. Blood Purif 2006; 24: 548-54.
8. Stevenson JM, Patel JH, Churchwell MD, et al. Ertapenem clearance during modeled continuous renal replacement therapy. Int J Artif Organs 2008; 31: 1027-34.
9. Golper TA. Drug removal during continuous hemofiltration or hemodialysis. In: Sieberth HG, Mann H, Stummvoll HK (eds). Continuous Hemofiltration. Contrib Nephrol 1991; vol 93: 110-16.
10. Vilay AM, Churchwell MD, Mueller BA. Drug metabolism and clearance in acute kidney injury. Crit Care 2008; 12: 235 (doi:10.1186/cc7093).
11. Rajewski RA, Stella VJ. Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery. J Pharm Sci 1996; 11: 1142-69.
12. Challa R, Ahuja A, Ali J, Khar RK. Cyclodextrins in drug delivery: An updated review. AAPS PharmSciTech 2005; 6: E329-57.
13. Irie T, Uekama K. Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J Pharm Sci 1997; 86: 147-62.
14. Mesens JL, Putteman P, Verheyen P. In: New trends in cyclodextrins and derivatives. Dechene D (ed). Editions de Santé: Paris; 1991. p 369-407.
15. Brunet S, Leblanc M, Geadah D, Parent D, Courteau S, Cardinal J. Diffusive and convective solute clearances during continuous renal replacement therapy at various dialysate and ultrafiltration flow rates. Am J Kidney Dis 1999; 34: 886-92.
16. Churchwell MD, Pasko DA, Btaiche IF, Jain J, Mueller BA. Trace element removal during in vitro and in vivo continuous hemodialysis. Nephrol Dial Transplant 2007; 22: 2970-77.
17. Pasko DA, Churchwell MD, Btaiche IF, Jain JC, Mueller BA. Continuous venovenous hemodiafiltration trace element clearance in pediatric patients: a case series. Pediatr Nephrol 2009; 24: 807-13.
18. Tian Q, Gomersall CD, Ip M, Tan PE, Joynt GM, Choi GYS. Adsorption of amikacin, a significant mechanism of elimination by hemofiltration. Antimicrob Agents Chemother 2008; 52: 1009-13.
19. Tian Q, Gomersall CD, Leung PPN, et al. The adsorption of vancomycin by polyacrylonitrile, polyamide and polsulfone hemofilters. Int J Artif Organs 2008; 32: 81-4.